N+1 Singer restated their buy rating on shares of Sinclair Pharma PLC (LON:SPH) in a research report report published on Tuesday morning, Marketbeat reports. N+1 Singer currently has a GBX 37 ($0.50) target price on the specialty pharmaceutical company’s stock.
Several other equities analysts also recently weighed in on the company. Peel Hunt reissued a buy rating and set a GBX 68 ($0.92) target price on shares of Sinclair Pharma PLC in a research report on Tuesday. Stifel Nicolaus reaffirmed a buy rating and issued a GBX 71 ($0.96) price objective on shares of Sinclair Pharma PLC in a research report on Tuesday, July 11th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of GBX 54 ($0.73).
Shares of Sinclair Pharma PLC (SPH) opened at 26.75 on Tuesday. The stock’s market cap is GBX 134.34 million. The company has a 50-day moving average price of GBX 29.00 and a 200-day moving average price of GBX 31.10. Sinclair Pharma PLC has a 52 week low of GBX 26.00 and a 52 week high of GBX 36.35.
About Sinclair Pharma PLC
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with our FREE daily email newsletter.